About | 苏州市代谢综合症新药研究重点实验室 Suzhou Municipal Key Lab for Metabolic Syndrome Drug Research
苏州市代谢综合症新药研究重点实验室成立于2010年，是国内首家代谢综合症新药重点实验室，拥有总投资超过4000万元的实验室，致力于从分子细胞水平探讨疾病的分子机理，系统及结构生物学，蛋白质及生物工程，细胞通信以及新型药物研发。实验室鼓励产学研合作，鼓励跨院系合作；对社会开放相关平台，分享科研仪器，为对应领域的学科研究提供支持。
代谢重点实验室研究主题 Metabolic Key Lab research themes
- 代谢综合征的分子机制
Molecular mechanism of Metabolic Syndrome—Theme Leader Dr. Jianrui Song
- 代谢综合征相关疾病的治疗、诊断和先进材料创新
Therapeutic, diagnostic, and advanced material innovations for metabolic syndrome-related diseases—Theme Leader Dr. Antony Kam
- 微生物群与代谢性疾病
Microbiota and Metabolic Diseases—Theme Leader Dr. Yongtao Zhu
代谢重点实验室的当前组织结构 Current organization of the Metabolic Key Lab
- Director: Dr. Weiwei Dai
- Associated Director: Dr. Jianrui Song
- Associated Director: Dr. Antony Kam
- External Collaboration Director: Dr. Yongtao Zhu
- Secretary: Xinhe Qi
- Metabolic Key Lab coordinator: Jingqi Xu
实验室主任 director: Dr. Weiwei Dai 代伟伟博士
实验室成员：
Theme 1: Molecular mechanism of Metabolic Syndrome—Theme Leader Dr. Jianrui Song
Dr. Weiwei Dai studies nitrogen metabolism in physiology and metabolic diseases including obesity and liver cancer, nutritional regulation of mTOR activation, and cancer metabolism.
Dr. Jianrui Song (AoP) investigate how obesity drives cancer progression, exploring itaconate's anti-inflammatory effects in cardiovascular disease.
Dr. Ken Cheng study regulatory mechanism investigation of bioactive compounds in metabolic diseases, and mass spectrometry-based analytical methods for comprehensive coverage of metabolome and lipidome.
Dr. Lanlan Han studies protein structures and engineers enhanced protein therapeutics.
Dr. Zhihao Jia (Suda/AoP) investigate the role of protein arginine methyltransferases and their substrates in adipose and muscle development and metabolism.
Dr. Mingming Xu (AoP) conduct drug discovery and mechanism studies for common neurodegenerative diseases, identifying exosomal biomarkers from biofluids for common cancers.
Dr. Zhimin Gu (ISM) focus on hematopoietic system development and hematologic malignancies, using high-throughput techniques to explore tumor mechanisms and develop new therapies.
Dr. Yu Feng (Suzhou University Second Affiliated Hospital (Sanxiang Rd Yuanqu)-Endocrinology Department) mass spectrometry and NMR-based metabolomics and lipidomics studies,make animal models,developing new strategies to treat metabolic disease.
Dr. Caifeng Jiang (Suzhou Dushuhu Hospital) Study chronic liver diseases, focusing on liver fibrosis mechanisms and cirrhosis complications, alongside liver cancer pathogenesis and early diagnosis and treatment of colorectal tumors.
Theme 2: Therapeutic, diagnostic, and advanced material innovations for metabolic syndrome-related diseases—Theme Leader Dr. Antony Kam
Dr. Antony Kam (BIO): Specializes in the design of novel peptides and proteins, the development of gene and cell therapies, the creation of diagnostic tests, the enhancement of drug delivery methods, the discovery of new medicines, and the investigation of mechanisms of action utilizing multi-omics technology.
Dr. Shining Loo (AoP): Concentrates on designing innovative peptides and proteins, creating gene and cell therapies, developing diagnostic tests, improving drug delivery methods, discovering new medicines, and studying mechanisms of action through multi-omics approaches.
Dr. Jeong Hyeon Park (BIO): Conducts research on drug mechanisms, discovers new drugs through molecular biology research, and develops gene delivery systems for therapeutic applications.
Dr. Kozo Hamada (BIO): Focuses on engineering biosensors for disease detection and designing therapeutic proteins for targeted interventions.
Dr. Francesco Zonta (BIO): Employs artificial intelligence and computational techniques to design antibodies and discover novel drug candidates.
Dr. Yong Shen (BIO): Specializes in constructing synthetic biological systems and employing genetic engineering for therapeutic applications in metabolic syndrome-related diseases.
Dr. Qiuchen Dong (CHEM): Concentrates on the development of advanced sensors and materials for sensing and monitoring metabolic syndrome-related diseases, enabling early detection and personalized treatment.
Dr. Xuan Xue (CHEM): Focuses on the development of cutting-edge biomaterials and polymers for targeted drug delivery and tissue engineering applications in metabolic syndrome-related diseases.
Dr. Chun Chan (BIO): Utilizes artificial intelligence integrated with computational biology approaches to drive innovative drug discovery for metabolic syndrome-related diseases.
Dr. Faez Khan (BIO): Conducts research on protein-protein interactions, engineers’ proteins for therapeutic purposes, designs drugs targeting specific protein targets, analyzes protein dynamics, and explores protein folding mechanisms in the context of MetS-related diseases.
Theme 3: Microbiota and Metabolic Diseases—Theme Leader Dr. Yongtao Zhu
Dr. Yongtao Zhu pure culturing, biochemical/physiological studying and genetic manipulation of microorganisms.
Dr. Min Tang host-specificity of gut symbionts, gut microbiome, and biological adaption.
Dr. Xinzhao Tong host-microbe interaction, human and built environment microbiome, and microbial ecology.
Dr. Lu Zhang microbial interactions in natural and engineered communities, meta-omics and isotope labelling.
